{
    "root": "fb8ba940-aef7-d17f-6539-6f3a73ae3a72",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Insulin Glargine",
    "value": "20250303",
    "ingredients": [
        {
            "name": "INSULIN GLARGINE",
            "code": "2ZM8CX04RZ"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "METACRESOL",
            "code": "GGO4Y809LO"
        },
        {
            "name": "ZINC CHLORIDE",
            "code": "86Q357L16B"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH"
        }
    ],
    "indications": "Insulin Glargine-yfgn is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.\n                  \n                     Limitations of Use\n                  \n                  Insulin Glargine-yfgn is not recommended for the treatment of diabetic ketoacidosis.",
    "contraindications": "• Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. ( 2.2 ) • Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. ( 2.1 ) • Do not dilute or mix with any other insulin or solution. ( 2.1 ) • Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. ( 2.1 ) • See Full Prescribing Information for the recommended starting dosage in patients with type 2 diabetes (2.3) and how to change to Insulin Glargine-yfgn from other insulins. ( 2.4 ) • Closely monitor glucose when switching to Insulin Glargine-yfgn and during initial weeks thereafter. ( 2.4 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "Insulin Glargine-yfgn is contraindicated:\n                  \n                     \n                        •During episodes of hypoglycemia [see Warnings and Precautions (5.3)]\n                     \n                     \n                        •In patients with hypersensitivity to insulin glargine products or any of the excipients in Insulin Glargine-yfgn [see Warnings and Precautions (5.5)]"
}